Healthcare, Pharma & Life Sciences

Bioinformatics Market to Hit $64.60B by 2034 on NGS, AI Demand

Image
Bioinformatics Market to Hit $64.60B by 2034 on NGS, AI Demand

Pune – September 25, 2026 -- The global bioinformatics market is projected to expand from $20.34 billion in 2025 to $64.60 billion by 2034, a 13.7% compound annual growth rate, according to new analysis from Maximize Market Research.

Genomic data volumes and NGS adoption fuel core demand

Rising volumes of genomic and biological data, driven by expanding next-generation sequencing (NGS) adoption, are pushing pharmaceutical and biotechnology companies toward advanced bioinformatics platforms, sequencing data analysis tools, and biological databases. Declining sequencing costs are drawing smaller research institutions into the market, while growing precision medicine applications are increasing demand for pharmacogenomics, biomarker analysis, and genomic diagnostics.

Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Image
Study: 55% of AD Patients Switch Systemic Therapy Over Efficacy Gaps

Friendswood, Texas – September 25, 2026 -- More than half of atopic dermatitis (AD) patients who used targeted systemic therapies modified treatment because the drugs failed to work, according to a new study published in Dermatology and Therapy by Castle Biosciences, Inc. (Nasdaq: CSTL).

Study finds 55% of systemic therapy users switched due to lack of efficacy

The research surveyed 43 AD patients and caregivers who completed a 32-question assessment at the 2024 National Eczema Association Eczema Expo. Among respondents who had used targeted systemic therapies, 55% reported modifying treatment because of insufficient results. Inadequate skin clearance and persistent itching were cited as the most frequent reasons for switching drugs or adding topical treatments.

NORD Honors Six Firms for First-of-Kind Rare Disease Therapy Approvals

Image
NORD Honors Six Firms for First-of-Kind Rare Disease Therapy Approvals

Norwell, Mass. – September 25, 2026 -- The National Organization for Rare Disorders (NORD) has named six companies and nonprofits as 2026 Industry Innovator honorees for delivering first-of-their-kind FDA-approved therapies to patients with rare diseases that affect a fraction of the more than 30 million Americans living with such conditions.

Six FDA approvals mark milestones across ultra-rare indications

Mighty Therapeutics was recognized for FORZINITY, the first therapy for Barth syndrome, a rare mitochondrial disease, shown to improve muscle strength and quality of life. UCB earned recognition for KYGEVVI, the first and only approved treatment for thymidine kinase 2 deficiency in patients whose symptoms began at or before age 12. Fondazione Telethon was honored for Waskyra, a gene therapy for Wiskott-Aldrich syndrome that stands as the first FDA-approved gene therapy for a primary immunodeficiency disorder and the first developed by a nonprofit.

RFU Neuroscientist Wins $2.3M NIH Grant to Study Teen Brain Isolation Effects

Image
RFU Neuroscientist Wins $2.3M NIH Grant to Study Teen Brain Isolation Effects

North Chicago, Illinois – September 25, 2026 -- Rosalind Franklin University of Medicine and Science (RFU) neuroscientist Nicole Ferrara, PhD, has secured a five-year, $2.3 million grant from the National Institutes of Health to investigate how social disruptions, including COVID-19 lockdowns, alter brain development in adolescents.

NIH funds five-year study on amygdala development and social behavior

The project, titled "Social Experience Guides BMA Mediated Social Development," will examine how the basomedial amygdala (BMA) responds to restricted or inconsistent social contact during adolescence and young adulthood. Dr. Ferrara's preliminary data indicate the BMA functions differently during teen and young adult years compared with other brain regions, making it potentially more vulnerable to social disruption.

NYU Langone Recruits Three Top Orthopedic Surgeons to Expand Sports Medicine

Image
NYU Langone Recruits Three Top Orthopedic Surgeons to Expand Sports Medicine

New York City – September 25, 2026 -- NYU Langone Health has recruited three senior orthopedic surgeons -- Dr. Sabrina M. Strickland, Dr. F. Winston Gwathmey, and Dr. Andreas H. Gomoll -- to lead new specialty centers within its orthopedics division, currently ranked No. 2 nationally by U.S. News & World Report.

NYU Langone builds out joint-preservation leadership with three senior hires

Dr. Strickland arrives from the Hospital for Special Surgery in Manhattan, where she practiced for more than two decades, to become the inaugural director of NYU Langone's new Center for Patellofemoral Disorders. Her clinical focus spans knee cartilage repair, patellar stabilization, ACL and meniscus surgery, and joint preservation; she also uses 3D-printed joint models to refine surgical techniques for patients with atypical bone structures, addressing a gap left by biomechanical research that relies primarily on cadaveric 'normal' joints.

The Inner Circle Names Dr. Lee Drinkard Pinnacle Lifetime Member

Image
The Inner Circle Names Dr. Lee Drinkard Pinnacle Lifetime Member

Irving, Texas – – September 25, 2026 -- The Inner Circle has named Dr. Lee Campbell Drinkard, MD, FACP, a Pinnacle Lifetime Member for his career in hematology, oncology and palliative care.

Drinkard practices locum tenens across multiple states, treating malignant and benign tumors

Dr. Drinkard currently works as a locum tenens physician, traveling nationwide to consult on complex hematology and oncology cases, including both malignant and benign tumors. His practice also extends to hospice and palliative care for patients managing life-limiting illness.

Drinkard holds four board certifications spanning internal medicine to palliative care

He is board certified in internal medicine, hematology, oncology, and hospice and palliative care. Drinkard is also a Fellow of the American College of Physicians, the credential reflected in his FACP designation.

MyOme Launches Global Genomic Risk Platform on Oracle Cloud

Image
MyOme Launches Global Genomic Risk Platform on Oracle Cloud

Menlo Park, Calif. – September 25, 2026 -- MyOme, Inc. has made its predictive genomic insights platform and testing services available worldwide by running them on Oracle Cloud Infrastructure (OCI), the companies announced.

MyOme joins Oracle PartnerNetwork to widen healthcare distribution

The clinical whole-genome analysis firm has also joined Oracle PartnerNetwork (OPN), enabling distribution of its capabilities through the Oracle ecosystem and Oracle Marketplace to a broader base of healthcare organizations.

Aria Care Partners Names Dr. Veda Lewis-Simmons Chief Medical Officer of Podiatry

Image
Aria Care Partners Names Dr. Veda Lewis-Simmons Chief Medical Officer of Podiatry

Overland Park, Kan. – September 25, 2026 -- Aria Care Partners has appointed Veda Lewis-Simmons, DPM, MHA, as chief medical officer of podiatry, giving her oversight of operational effectiveness and clinical quality for the company's onsite podiatry services across skilled nursing facilities (SNFs).

Aria Care Partners taps board-certified podiatrist to lead clinical quality for SNF foot care programs

Dr. Lewis-Simmons holds a master's degree in healthcare administration and a Doctor of Podiatric Medicine and Surgery from Des Moines University Medicine and Health Sciences. She completed her residency at the University of Texas Health Science Center in San Antonio and is board certified.

ACROBiosystems Launches CHO-Direct, ACRO AIx for AI Drug Discovery

San Diego – September 25, 2026 -- ACROBiosystems has launched CHO-Direct, a rapid high-throughput affinity validation service that delivers antibody affinity data in as little as four days from sequence submission, alongside a broader infrastructure platform called ACRO AIx aimed at AI-driven drug discovery (AIDD).

CHO-Direct compresses antibody validation timelines to four days

Using an optimized CHO cell system, CHO-Direct converts computationally generated antibody sequences into structured affinity data within days, addressing a bottleneck where AI tools generate candidate sequences faster than labs can validate them. The service leverages the protein-folding and post-translational modification environment of mammalian cells while maintaining compatibility with CHO systems already used in downstream development and manufacturing.

Jiro: CMS Modifier 25 Plan Would Shift $889M, Hit Private Practices

Image
Jiro: CMS Modifier 25 Plan Would Shift $889M, Hit Private Practices

Austin, Texas – September 25, 2026 -- A proposed Medicare payment change involving Modifier 25 would reallocate approximately $889 million in annual fee-for-service payments, with private practices and solo physicians absorbing $724.4 million, or 81.5%, of the modeled reductions, according to a new analysis from Jiro Health.

Six specialties bear 82.3% of the total reduction

Jiro's Practice Impact Analysis, titled "Who Pays for CMS's Modifier 25 Proposal?", found that six medical specialties account for roughly $732 million of the modeled impact. Dermatology alone represents $395.4 million, or 44.5% of the total reallocation. Podiatric medicine and surgery, orthopaedic surgery, otolaryngology, ophthalmology and family medicine together account for an additional $336 million.